XAFTY®

Host-Directed Antiviral Platform 

Rather than directly targeting viruses, XAFTY® acts on shared host-driven disease mechanisms, allowing broad-spectrum use across diverse viral infections. It is currently being clinically evaluated against multiple viruses, including COVID-19, RSV, Influenza, and Dengue. 

 Prepared for the Next Viruses

A broad spectrum antiviral platform for rapid response

XAFTY® is a broad-spectrum antiviral platform designed to enable an immediate response even to emerging, previously unknown viruses like Disease X. Even in the event of future pandemics such as SARS, MERS, or COVID-19, it can serve as a therapeutic bridge, supporting response efforts during the critical early phase before vaccines become available.